# Modulo Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/modulo-bio

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.modulo.bio
- Total disclosed funding: $3.9M
- Latest round: Seed (Jun 8, 2021)
- Investors on record: 7

## About

Founded in 2021 and based in California, US, Modulo Bio, Inc. operates as a biotechnology company that researches and develops drugs focused on the neuroimmune system. In March 2025, Modulo Bio, Inc. raised USD 4.8 million in venture funding from new investor Alzheimer's Drug Discovery Foundation. As of March 2025, the company is being led by its founders Michael Horowitz (CEO), Justin Ichida, and Scott Patterson (CTO). The Modulo Neuroimmune Platform, developed by the company, combines software, automation, and artificial intelligence with stem cell biology and neuroscience to pioneer new treatments for patients suffering from debilitating neurodegenerative diseases. The company creates therapeutic drugs that reprogram the neuroimmune system in order to slow or reverse disease progression. The company will use the March 2025 funding to advance the development of its CSF1R inhibitor for treating amyotrophic lateral sclerosis and frontotemporal dementia.

## Funding rounds

- Seed, Jun 8, 2021, $3.9M — Initialized Capital, Refactor Capital, Cantos Ventures, Builders VC, Bioverge, Spacecadet Ventures, Hawktail

## Investors

- Initialized Capital (https://capitalatlas.ai/funds/initialized-capital) — Seed
- Refactor Capital (https://capitalatlas.ai/funds/refactor-capital) — Seed
- Cantos Ventures (https://capitalatlas.ai/funds/cantos-ventures) — Seed
- Builders VC (https://capitalatlas.ai/funds/builders-vc) — Seed
- Bioverge (https://capitalatlas.ai/funds/bioverge) — Seed
- Spacecadet Ventures (https://capitalatlas.ai/funds/spacecadet-ventures) — Seed
- Hawktail (https://capitalatlas.ai/funds/hawktail) — Seed